Unapproved peptides: claims, records and safety questions

Start with the Australian safety position

In June 2026, the TGA and Australia’s Chief Medical Officer warned about public-health risks associated with unapproved peptide products. The notice names BPC-157, GHK-Cu and TB-500 among products that may not have been evaluated by the TGA for safety, quality or effectiveness when they are not included in the Australian Register of Therapeutic Goods.

The TGA also identifies unknown manufacturing conditions, ingredient uncertainty and sterile preparation of injectables as consumer-safety concerns. A confident product description cannot answer those questions.

Sources checked 6 September 2026: TGA and Chief Medical Officer, concerns about unapproved peptide products

Do not turn an internet claim into a protocol

This page intentionally does not provide use protocols, sourcing or administration instructions. Those details can make an unapproved product claim look like an established treatment when the identity, quality and human safety information may be uncertain.

If you are considering a peptide product, discuss the specific product, intended use, current medicines and health history with a qualified healthcare professional. The TGA advises Australians not to purchase or use unapproved peptide products, particularly products obtained online or from overseas.

Sources checked 6 September 2026: TGA and Chief Medical Officer, concerns about unapproved peptide products · TGA, about registered complementary medicines

Keep a safety-focused record

If you have used a product or have had an unwanted effect, keep packaging details, dates, route described on the label, other medicines and the symptoms you observed. Seek clinical advice promptly for concerning symptoms. The TGA asks consumers to report suspected adverse events so it can monitor safety concerns.

Sources checked 6 September 2026: TGA and Chief Medical Officer, concerns about unapproved peptide products